Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose MOUNTAIN VIEW, Calif. / May 29, 2025 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage... Read More

MOUNTAIN VIEW, Calif. / May 28, 2025 / Business Wire / Alto Neuroscience, Inc . (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5 th... Read More

Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 New data presented at recent scientific... Read More

Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD New data strengthen the mechanistic link between ALTO-300 and the EEG biomarker being used for patient selection; biomarker signature induced by activating 5-HT2C or depleting dopamine directly Preclinical ALTO-101 rescue study underscores the therapeutic potential of this novel PDE4 inhibitor, and validates EEG theta response as a... Read More

MOUNTAIN VIEW, Calif. / Apr 22, 2025 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor... Read More

Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia... Read More

SINGAPORE , March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox , as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's... Read More

MOUNTAIN VIEW, Calif. / Feb 25, 2025 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March: TD Cowen 45 th Annual Health Care Conference, March... Read More

Patent supports Alto’s precision approach to improve patient selection MOUNTAIN VIEW, Calif. / Feb 19, 2025 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims... Read More

Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample Topline results are expected in mid-2026 The company recently reported an estimated preliminary 2024 year-end cash balance of approximately $168 million, which is expected to support planned operations into 2028 MOUNTAIN VIEW, Calif. / Feb 12, 2025 / Business Wire / Alto... Read More

Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive... Read More

Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary... Read More

MOUNTAIN VIEW, Calif. / Nov 04, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in November: Stifel 2024 Healthcare Conference, November 18-19... Read More

Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker ALTO-100 demonstrated a favorable safety and tolerability profile, consistent with previously reported studies Strong cash position expected to fund Alto’s planned operations through multiple near-term milestones across pipeline of independent programs MOUNTAIN VIEW, Calif. /... Read More

Despite its reported benefits for aspects of cognition, vortioxetine does not demonstrate greater clinical efficacy in major depressive disorder (MDD) patients with cognitive impairment Findings further underscore the importance of developing ALTO-100 in depression characterized by poor cognition MOUNTAIN VIEW, Calif. / Sep 04, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage... Read More

Alto to host investor day focused on ALTO-100 on September 9, 2024 MOUNTAIN VIEW, Calif. / Sep 03, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and... Read More

Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100; Investor Day focused on ALTO-100 planned for September 9, 2024; topline data expected in October 2024 Initiated multiple Phase 2 studies: ALTO-101 in schizophrenia, ALTO-203 in MDD with anhedonia, and ALTO-100 in bipolar depression Reported positive Phase 1 data on transdermal formulation of our novel PDE4 inhibitor, ALTO-101 Strong cash position of... Read More

$11.7 million award will be used to advance ALTO-100, a first-in-class small molecule, in a 200-patient placebo-controlled, double-blind, randomized Phase 2b study in bipolar depression Alto will leverage the same cognitive biomarker being used in the ongoing Phase 2b MDD, which was previously identified and replicated in MDD and PTSD patients This study represents the first precision psychiatry trial in bipolar depression,... Read More

300 patients enrolled in the study, including patients with and without the cognitive biomarker On track to report topline data in October 2024 Alto to host investor day focused on ALTO-100 on September 9, 2024 MOUNTAIN VIEW, Calif. / Jul 16, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for... Read More

ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally Novel transdermal formulation of ALTO-101 exhibited favorable pharmacokinetics and tolerability, greater drug exposure, and fewer PDE4 associated adverse events compared to ALTO-101 administered orally LOS ALTOS, Calif. / Jun 20, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)... Read More

Dr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future across all industries LOS ALTOS, Calif. / Jun 18, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award... Read More

LOS ALTOS, Calif. / May 29, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m. ET, and management will host one-on-one... Read More

Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia LOS ALTOS, Calif. / May 21, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as... Read More

Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia Reported positive Phase 1 data with transdermal formulation of novel PDE4 inhibitor, ALTO-101; achieved significantly greater drug exposure with improved tolerability compared to oral administration Patient enrollment on track across Phase 2b MDD studies for ALTO-100 and ALTO-300 Strong cash position of approximately $206 million expected to support... Read More

Breadth of Alto’s pipeline and Precision Psychiatry Platform™ will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical Psychopharmacology Annual Meetings Presented comprehensive identification and prospective replication of neurobiological markers linked to cognitive impairment associated with schizophrenia; Results inform design of planned ALTO-101... Read More

ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated with PDE4 inhibitors First-in-human achievement of target exposure with proprietary transdermal patch formulation developed in... Read More

Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder (MDD) and higher levels of anhedonia ALTO-203 demonstrated a favorable tolerability profile across three Phase 1 clinical trials and produced a variety of emotional and brain effects that support its unique antidepressant potential LOS ALTOS, Calif. / Apr 03, 2024 /... Read More

Reported positive results from ALTO-100 and ALTO-300 Phase 2a studies demonstrating prospective replication of response prediction using Alto’s Precision Psychiatry Platform™ Patient enrollment on track across Phase 2b MDD studies for two lead product candidates Successful completion of oversubscribed initial public offering; cash position of approximately $210 million as of February 29, 2024 LOS ALTOS, Calif. / Mar 21, 2024... Read More

Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function LOS ALTOS, Calif. / Mar 11, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company’s board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades... Read More

LOS ALTOS, Calif. / Mar 07, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Biotech on the Bay Summit, March 12-13 th : Alto management will participate in one-on-one meetings with investors during the conference. UBS Virtual CNS Day, March 18 th : Amit Etkin, M.D., Ph.D., founder and chief... Read More

LOS ALTOS, Calif. / Feb 27, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44 th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET. The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of... Read More

LOS ALTOS, Calif. / Feb 06, 2024 / Business Wire / Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,206,000 additional shares, at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the... Read More

LOS ALTOS, Calif.--( BUSINESS WIRE )-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses... Read More